At the 5th HIV Research for Prevention Conference (HIVR4P) in Peru, groundbreaking data on the lenacapavir injection revealed its remarkable efficacy in HIV prevention. With a single injection every six months, the drug completely halted new HIV infections among women and girls. It achieved a 96% risk reduction for other gender-diverse individuals aged 16 and up. Despite lenacapavir’s transformative potential,…